- Ability Pharma

ABILITYPHARMA

AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer

PIPELINE

ABTL0812, first-in-class, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and lung cancer in Spain and France.

SCIENCE

AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.

Media Center

05.06.2025

Press Release

AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer + info

09.09.2024

Press Release

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info

29.12.2020

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info

29.12.2020

In the media

The Chinese SciClone enters at the biotech Ability Pharma + info

Events

September 13-17 . ESMO Congress Barcelona + info

Events

June 3-6 BIO . San Diego (USA) + info